186 related articles for article (PubMed ID: 38277756)
1. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.
Kim Y; Jung KY; Kim YH; Xu P; Kang BE; Jo Y; Pandit N; Kwon J; Gariani K; Gariani J; Lee J; Verbeek J; Nam S; Bae SJ; Ha KT; Yi HS; Shong M; Kim KH; Kim D; Jung HJ; Lee CW; Kim KR; Schoonjans K; Auwerx J; Ryu D
Drug Resist Updat; 2024 Mar; 73():101054. PubMed ID: 38277756
[TBL] [Abstract][Full Text] [Related]
2. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome.
Samir P; Kesavardhana S; Patmore DM; Gingras S; Malireddi RKS; Karki R; Guy CS; Briard B; Place DE; Bhattacharya A; Sharma BR; Nourse A; King SV; Pitre A; Burton AR; Pelletier S; Gilbertson RJ; Kanneganti TD
Nature; 2019 Sep; 573(7775):590-594. PubMed ID: 31511697
[TBL] [Abstract][Full Text] [Related]
3. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24.
Hu Z; Zhao Y; Mang Y; Zhu J; Yu L; Li L; Ran J
Life Sci; 2023 Jul; 325():121773. PubMed ID: 37187452
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma.
Yanai M; Kurata M; Muto Y; Iha H; Kanao T; Tatsuzawa A; Ishibashi S; Ikeda M; Kitagawa M; Yamamoto K
Pathology; 2020 Aug; 52(5):529-537. PubMed ID: 32586688
[TBL] [Abstract][Full Text] [Related]
5. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
6. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
7. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
8. AKT controls NLRP3 inflammasome activation by inducing DDX3X phosphorylation.
Guo X; Chen S; Yu W; Chi Z; Wang Z; Xu T; Zhang J; Jiang D; Guo Y; Fang H; Zhang K; Li M; Yang D; Yu Q; Ye Q; Wang D; Zhang X; Wu Y
FEBS Lett; 2021 Oct; 595(19):2447-2462. PubMed ID: 34387860
[TBL] [Abstract][Full Text] [Related]
9. DDX3X Links NLRP11 to the Regulation of Type I Interferon Responses and NLRP3 Inflammasome Activation.
Kienes I; Bauer S; Gottschild C; Mirza N; Pfannstiel J; Schröder M; Kufer TA
Front Immunol; 2021; 12():653883. PubMed ID: 34054816
[TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
11. TLR4 aggravates microglial pyroptosis by promoting DDX3X-mediated NLRP3 inflammasome activation via JAK2/STAT1 pathway after spinal cord injury.
Wang J; Zhang F; Xu H; Yang H; Shao M; Xu S; Lyu F
Clin Transl Med; 2022 Jun; 12(6):e894. PubMed ID: 35692100
[TBL] [Abstract][Full Text] [Related]
12. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
14. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
15. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
16. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells.
Chen CT; Liao LZ; Lu CH; Huang YH; Lin YK; Lin JH; Chow LP
Exp Mol Med; 2020 Mar; 52(3):497-513. PubMed ID: 32203105
[TBL] [Abstract][Full Text] [Related]
17. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
19. DDX3X coordinates host defense against influenza virus by activating the NLRP3 inflammasome and type I interferon response.
Kesavardhana S; Samir P; Zheng M; Malireddi RKS; Karki R; Sharma BR; Place DE; Briard B; Vogel P; Kanneganti TD
J Biol Chem; 2021; 296():100579. PubMed ID: 33766561
[TBL] [Abstract][Full Text] [Related]
20. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
